Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) Congresses
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced preclinical data for REX-8756, an oral, potent and selective STAT6 inhibitor, is being presented at two upcoming scientific congresses. At the European Association of Allergy and Clinical Immunology (EAACI) Congress taking place June 12-15, 2026, in Istanbul, Turkey, a poster will highlight data with REX-8756 from in vivo models of allergic asthma and dermatitis. At the Revolutionizing Atopic Dermatitis (RAD) Congress taking place June 17-19, 2026, in Nashville, TN, data from a preclinical model of atopic dermatitis and an in vivo pharmacokinetic and pharmacodynamic (PK/PD) model will be featured in a poster presentation.